RxDoctor Payments Data

Steven Gershon, MD

Pain Medicine · Virginia Beach, VANPI 1073541736

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (41.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 59 manufacturers reported payments, led by AbbVie at 45.7% of the total. Reporting peaked in 2023 at $36,761 and has fallen 70.2% since, to $10,963 in 2025. Among pain medicine clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$78,076in general payments, 2019–2025

Across 548 payments — averaging $142.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$36K
  • Kowa Pharmaceuticals America, Inc.$24K
  • Vertex$9K
  • Nevro Corp.$825
  • Lundbeck LLC$658
  • Pfizer$613
  • plus $7K from 53 others
$518,786in research payments, 2019–2025

Across 51 payments — averaging $10,172 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Seikagaku Corporation$509K
  • Eli Lilly$10K

What the payments were for

  • Consulting fees$31,29040%
  • Speaking & faculty fees$32,43842%
  • Travel & lodging$1,5702%
  • Food & beverage$12,77216%
  • Education$70%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)202$35,671
Kowa Pharmaceuticals America, Inc.19$24,403
Vertex17$9,383
Nevro Corp.14$825
Lundbeck LLC24$658
Pfizer38$613
Boston Scientific6$520
Medtronic(2 entities)7$415
Lilly USA, LLC16$344
Amgen(2 entities)11$324
Bioventus LLC9$310
Abbott11$293
Merz Pharmaceuticals, LLC10$280
Avanir Pharmaceuticals, Inc.9$250
Fidia Pharma USA Inc.10$232
Novartis12$226
Biohaven Pharmaceuticals, Inc.6$209
Si-bone, Inc.5$200
Stimwave Technologies Incorporated3$183
Ipsen Biopharmaceuticals, Inc8$169
Intrinsic Therapeutics1$168
Relievant Medsystems, Inc.2$156
Eisai Inc.3$153
Globus Medical2$133
Collegium Pharmaceutical, Inc.6$123
IBSA Pharma Inc.5$116
Medical Device Business Services, Inc.1$114
Teva Pharmaceuticals USA, Inc.7$113
Biodelivery Sciences International, Inc.6$100
Johnson & Johnson3$97
Merck5$90
SPR Therapeutics, Inc4$88
Scilex Pharmaceuticals Inc.5$85
Almatica Pharma LLC5$82
Arbor Pharmaceuticals, Inc.5$77
Electronic Waveform Lab, Inc.5$77
Currax Pharmaceuticals LLC5$76
Zyla Life Sciences, Inc.5$69
MDD US Operations, LLC5$69
Biohaven Pharmaceutical Holding Company Ltd.4$59
Assertio Therapeutics, Inc.3$48
Tonix Medicines, Inc.2$47
Azurity Pharmaceuticals, Inc.2$44
Impel Pharmaceuticals Inc.2$41
Kaleo, Inc.2$38
Avanos Medical2$36
Painteq LLC1$34
Hikma Pharmaceuticals USA2$32
Curonix LLC1$32
Biogen1$27
Ultragenyx Pharmaceutical Inc.1$18
Pacira Therapeutics, Inc.1$18
Ferring Pharmaceuticals Inc.1$17
GRT US Holding, Inc.1$17
Averitas Pharma Inc.1$16
AstraZeneca1$15
Baudax Bio Inc.1$15
Sanofi-aventis U.S. LLC1$14
Vertical Pharmaceuticals, LLC1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$78,076 in reported general payments places this provider in the 95th percentile of 150 pain medicine providers in Virginia.

See all pain medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$435,241
Medicare patients
826
Services billed
7,431

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gabapentin12$292
Acetaminophen-CodeineAcetaminophen With Codeine12$199

Paid to pharmacies, not to this prescriber.

Other pain medicine in Virginia Beach

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →